Autism: The role of cholesterol in treatment

International Review of Psychiatry

Volumn 20, Issue 2, 2008, Pages 165-170

  Aneja, Alka ^a   Tierney, Elaine ^b  

^a KENNEDY KRIEGER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

7 DEHYDROCHOLESTEROL; 7 DEHYDROCHOLESTEROL REDUCTASE; CHOLESTEROL; GUANINE NUCLEOTIDE BINDING PROTEIN; MYELIN; OXIDOREDUCTASE; OXYTOCIN RECEPTOR; SEROTONIN 1A RECEPTOR; UNCLASSIFIED DRUG;

AGGRESSION; ALGORITHM; ANGER; AUTISM; AUTOMUTILATION; BODY GROWTH; CHILD; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CLINICAL FEATURE; DIET SUPPLEMENTATION; EMBRYO DEVELOPMENT; ENZYME ACTIVITY; FETUS DEVELOPMENT; HUMAN; HYPERACTIVITY; IRRITABILITY; LIGAND BINDING; MYELIN SHEATH; PRIORITY JOURNAL; REVIEW; SLEEP; SMITH LEMLI OPITZ SYNDROME; SOCIAL INTERACTION; SYMPTOM; TRICHOTILLOMANIA;

AUTISTIC DISORDER; CHILD; CHOLESTEROL; HUMANS; PHENOTYPE; SMITH-LEMLI-OPITZ SYNDROME;

EID: 41749102426     PISSN: 09540261     EISSN: 13691627     Source Type: Journal    
DOI: 10.1080/09540260801889062     Document Type: Review

References (36)

1. Allen, J. A., Halverson-Tamboli, R. A., & Rasenick, M. M. (2007). Lipid raft microdomains and neurotransmitter signalling. Nature Reviews Neuroscience, 8, 128-140.
2. Centers for Disease Control (CDC). (2007). Morbidity and Mortality Weekly Report Surveillance Summaries. http://www.cdc.gov/MMWR/pdf/ss/ss5601. pdf (Accessed February 9).
3. Chattopadhyay, A., Jafurulla, M., Kalipatnapu, S., Pucadyil, T. J., & Harikumar, K. G. (2005). Role of cholesterol in ligand binding and G-protein coupling of serotonin1A receptors solubilized from bovine hippocampus. Biochem Biophys Res Commun, 327, 1036-1041.
4. Correa-Cerro, L. S., Wassif, C. A., Kratz, L., Miller, G. F., Munasinghe, J. P., Grinberg, A., et al. (2006). Development and characterization of a hypomorphic Smith-Lemli-Opitz syndrome mouse model and efficacy of simvastatin therapy. Hum Mol Genet, 15(6), 839-851.
5. Filipek, P. A., Accardo, P. J., Ashwal, S., Baranek, G. T., Cook, E. H. Jr, Dawson, G., et al. (2000). Practice parameter: Screening and diagnosis of autism: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Child Neurology Society. Neurology, 55, 468-479.
6. Fitzky, B. U., Witsch-Baumgartner, M., Erdel, M., Lee, J. N., Paik, Y. K., Glossmann, H., et al. (1998). Mutations in the Delta7-sterol reductase gene in patients with the Smith-Lemli-Opitz syndrome. Proc Natl Acad Sci USA, 95(14), 8181-8186.
7. Geschwind, D. H., Sowinski, J., Lord, C., Iversen, P., Shestack, J., Jones, P., et al. (2001). The autism genetic resource exchange: A resource for the study of autism and related neuropsychiatric conditions. American Journal of Human Genetics, 69(2),463-466.
8. Gimpl, G., Wiegand, V., Burger, K., & Fahrenholz, F. (2002). Cholesterol and steroid hormones: Modulators of oxytocin receptor function. Prog Brain Res, 139, 43-55.
9. Hollander, E., Bartz, J., Chaplin, W., Phillips, A., Sumner, J., Soorya, L., et al. (2007). Oxytocin increases retention of social cognition in autism. Biol Psychiatry, 61(4), 498-503.
10. Irons, M., Elias, E. R., Abuelo, D., Bull, M. J., Greene, C. L., Johnson, V. P., et al. (1997). Treatment of Smith-Lemli-Opitz syndrome: Results of a multicenter trial. American Journal of Medical Genetics, 68, 311-314.
11. Irons, M., Elias, E. R., Abuelo, D., Tint, G. S., & Salen, G. (1995). Clinical features of the Smith-Lemli-Opitz syndrome and treatment of the cholesterol metabolic defect. International Pediatrics, 10, 28-32.
12. Jira, P. E., Wevers, R. A., de Jong, J., Rubio-Gozalbo, E., Janssen-Zijlstra, F. S., van Heyst, A. E., et al. (2000). Simvastatin. A new therapeutic approach for Smith-Lemli-Opitz syndrome. Journal of Lipid Research, 41(8), 1339-1346.
13. Lord, C., Rutter, M., & Le Couteur, A. (1994). Autism Diagnostic Interview - Revised: A revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. Journal of Autism and Developmental Disorders, 24, 659-685.
14. Lund, E., Sisfontes, L., Reihner, E., & Bjorkhem, I. (1989). Determination of serum levels of unesterified lathosterol by isotope dilution-mass spectrometry. Scandinavian Journal of Clinical and Laboratory Investment, 49(2), 165-171.
15. Marcos, J., Guo, L. W., Wilson, W. K., Porter, F. D., & Shackleton, C. (2004). The implications of 7-dehydrosterol-7-reductase deficiency (Smith-Lemli-Opitz syndrome) to neurosteroid production. Steroids, 69, 51-60.
16. Muhle, R., Trentacoste, S. V., & Rapin, I. (2004). The genetics of autism. Pediatrics, 113, e472-e486.
17. Nowaczyk, M. J. M., & Tierney, E. (2004). Smith-Lemli-Opitz syndrome: Demystifying genetic syndromes (pp. 207-223). Kingston, NY: National Association for the Dually Diagnosed Publishing.
18. Nowaczyk, M. J. M., & Waye, J. S. (2001). The Smith-Lemli-Opitz syndrome: A novel metabolic way of understanding developmental biology, embryogenesis and dysmorphology. Clinical Genetics, 59, 75-76.
19. Nwokoro, N. A., & Mulvihill, J. J. (1997). Cholesterol and bile acid replacement therapy in children and adults with Smith-Lemli-Opitz (SLO/RSH) syndrome. American Journal of Medical Genetics, 68, 315-321.
20. Opitz, J. M. (1999). RSH (so called Smith-Lemli-Opitz) syndrome. Current Opinions in Pediatrics, 11, 353-362.
21. Pisu, M. G., & Serra, M. (2004). Neurosteroids and neuroactive drugs in mental disorders. Life Science, 74, 3181-3197.
22. Ryan, A. K., Bartlett, K., Clayton, P., Eaton, S., Mills, L., Donnai, D., et al. (1998). Smith-Lemli-Opitz syndrome: A variable clinical and biochemical phenotype. Journal of Medical Genetics, 35, 558-565.
23. Saher, G., Brugger, B., Lapper-Siefke, C., Mobius, W., Tozawa, R., Wehr, M. C., et al. (2005). High cholesterol level is essential for myelin membrane growth. Nat Neuroscience, 8, 468-475.
24. Sikora, D. M., Pettit-Kekel, K., Penfield, J., Merkens, L. S., & Steiner, R. D. (2006). The near universal presence of autism spectrum disorders in children with Smith-Lemli-Opitz syndrome. Am J Med Genet Part A, 140, 1511-1518.
25. Sikora, D. M., Ruggiero, M., Petit-Kekel, K., Merkens, L. S., Connor, W. E., & Steiner, R. D. (2004). Cholesterol supplementation does not improve developmental progress in Smith-Lemli-Opitz syndrome. Journal of Pediatrics, 144(6), 783-791.
26. Smith, D. W., Lemli, L., & Opitz, J. M. (1964). A newly recognized syndrome of multiple congenital anomalies. Journal of Pediatrics, 64, 210-217.
27. Strous, R. D., Golubchik, P., Maayan, R., Mozes, T., Tuati-Werner, D., Weizman, A., et al. (2005). Lowered DHEA-S plasma levels in adult individuals with autistic disorder. European Neuropsychopharmacology, 15, 305-309.
28. Tabin, C. J., & McMahon, A. P. (1997). Recent advances in hedgehog signalling. Trends in Cell Biology, 7(11), 442-446.
29. Tierney, E., Bukelis, I., Thompson, R. E., Ahmed, K., Aneja, A., Kratz, L., et al. (2006). Abnormalities of cholesterol metabolism in autism spectrum disorders. American Journal of Medical Genetics Part B, 141B, 666-668.
30. Tierney, E., Nwokoro, N. A., & Kelley, R. I. (2000). Behavioral phenotype of RSH/Smith-Lemli-Opitz syndrome. Mental Retardation and Developmental Disabilities Research Reviews, 6(2), 131-134.
31. Tierney, E., Nwokoro, N. A., Porter, F. D., Freund, L. S., Ghuman, J. K., & Kelley, R. I. (2001). Behavior phenotype in the RSH/Smith-Lemli-Opitz syndrome. American Journal of Medical Genetics, 98, 191-200.
32. Tint, G. S., Irons, M., Elias, E. R., Batta, A. K., Frieden, R., Chen, T. S., et al. (1994). Defective cholesterol biosynthesis associated with the Smith-Lemli-Opitz syndrome. New England Journal of Medicine, 330, 107-113.
33. Waage-Baudet, H., Lauder, J. M., Dehart, D. B., Kluckman, K., Hiller, S., Tint, G. S., et al. (2003). Abnormal serotonergic development in a mouse model for the Smith-Lemli-Opitz syndrome: Implications for autism. International Journal for Developmental Neuroscience, 21, 451-459.
34. Wassif, C. A., Krakowiak, P. A., Wright, B. S., Gewandter, J. S., Sterner, A. L., Javitt, N., et al. (2005). Residual cholesterol synthesis and simvastatin induction of cholesterol synthesis in Smith-Lemli-Opitz syndrome fibroblasts. Mol Genet Metab, 85(2), 96-107.
35. Wassif, C. A., Maslen, C., Kachilele-Linjewile, S., Lin, D., Linck, L. M., Connor, W. E., et al. (1998). Mutations in the human sterol delta7-reductase gene at 11q12-13 cause Smith-Lemli-Opitz syndrome. American Journal of Human Genetics, 63(1), 55-62.
36. Zimmerman, A. W. (2005). Autism spectrum disorders. In S. Singer, E. H. Kossof, A. L. Hartman & T. O. Crawford (Eds.), Treatment of pediatric neurologic disorders (pp. 489-494). Boca Raton: Taylor and Francis.